U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07084896) titled 'Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM' on July 22.
Brief Summary: The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
Study Start Date: June 08, 2020
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: Belantamab mafodotin
Belantamab mafodotin will be administered...